Current therapy for acromegaly

Trends in Endocrinology and Metabolism

Volumn 11, Issue 4, 2000, Pages 128-132

  Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PEGVISOMANT; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; DISABILITY; DRUG USE; GROWTH HORMONE BLOOD LEVEL; MORTALITY; PRIORITY JOURNAL; REVIEW; TRANSSPHENOIDAL HYPOPHYSECTOMY;

ACROMEGALY; DOPAMINE AGONISTS; GROWTH HORMONE; HUMANS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 0034052902     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00244-7     Document Type: Review

References (35)

1. Melmed S. Acromegaly. New Engl. J. Med. 322:1990;966-977.
2. Barkan A.L.et al. Increased growth hormone pulse frequency in acromegaly. J. Clin. Endocrinol. Metab. 69:1989;1225-1233.
3. Rosen T., Bengtsson B-A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 336:1990;285-288.
4. Bates A.S.et al. An audit of outcome of treatment in acromegaly. Q. J. Med. 86:1993;293-299.
5. Rajasoorya C.et al. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. 41:1994;95-102.
6. Orme S.M.et al. Mortality and cancer incidence in acromegaly. a retrospective cohort study. United Kingdom acromegaly study group J. Clin. Endocrinol. Metab. 83:1998;2730-2734.
7. Abosch A.et al. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas. initial outcome and long-term results J. Clin. Endocrinol. Metab. 83:1998;3411-3418.
8. Swearingen B.et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83:1998;3419-3426.
9. Jenkins D.et al. The Birmingham pituitary database. auditing the outcome of the treatment of acromegaly Clin. Endocrinol. 43:1995;517-522.
10. Sheaves R.et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin. Endocrinol. 45:1996;407-413.
11. Lissett C.A.et al. The outcome of surgery for acromegaly. the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma Clin. Endocrinol. 49:1998;653-657.
12. Ross D.A., Wilson C.B. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J. Neurosurg. 68:1988;854-867.
13. Tindall G.T.et al. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly. outcome analysis and determinants of failure J. Neurosurg. 78:1993;205-215.
14. Fahlbusch R.et al. Surgical management of acromegaly. Endocrinol. Metab. Clin. North Am. 21:1992;669-692.
15. Osman I.A.et al. Factors determining the long-term outcome of surgery for acromegaly. Q. J. Med. 87:1994;617-623.
16. Yamada S.et al. Retrospective analysis of long-term surgical results in acromegaly. preoperative and postoperative factors predicting outcome Clin. Endocrinol. 45:1996;291-298.
17. Ahmed S.et al. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin. Endocrinol. 50:1999;561-568.
18. Gittoes N.J.L.et al. Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. Q. J. Med. 92:1999;741-745.
19. Burch W. A survey of results with transsphenoidal surgery in Cushing's disease. New Engl. J. Med. 308:1983;103-104.
20. Jaffe C.A., Barkan A.L. Treatment of acromegaly with dopamine agonists. Endocrinol. Metab. Clin. North Am. 21:1992;713-735.
21. Abs R.et al. Cabergoline in the treatment of acromegaly. a study in 64 patients J. Clin. Endocrinol. Metab. 83:1998;374-378.
22. Vance M.L., Harris A.G. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch. Intern. Med. 151:1991;1573-1578.
23. Sassolas G.et al. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J. Clin. Endocrinol. Metab. 71:1990;391-397.
24. Newman C.B.et al. Safety and efficacy of long-term octreotide therapy of acromegaly. results of a multicenter trial in 103 patients - a clinical research center study J. Clin. Endocrinol. Metab. 80:1993;2768-2775.
25. Grass P.et al. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly. pharmacokinetic and pharmacodynamic relationships Metabolism. 45:1996;27-30.
26. Stewart P.M.et al. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J. Clin. Endocrinol. Metab. 80:1995;3267-3272.
27. Lancranjan I.et al. Results of a European multicentre study with sandostatin LAR in acromegalic patients. Pituitary. 1:1999;105-114.
28. Heron I.et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 76:1993;721-727.
29. Flogstad A.K.et al. Sandostatin-LAR in acromegalic patients. long-term treatment J. Clin. Endocrinol. Metab. 81:1997;23-28.
30. Davies P.H.et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin. Endocrinol. 48:1998;311-316.
31. Caron P.et al. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab. 82:1997;18-22.
32. Turner H.E.et al. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin. Endocrinol. 51:1999;275-280.
33. Trainer P.J.et al. Treatment of acromegaly with Pegvisomant, a genetically engineered human growth-hormone receptor antagonist. New Engl. J. Med. 200;. (in press).
34. Newman N.et al. Octreotide as primary therapy for acromegaly. J. Clin. Endocrinol. Metab. 83:1998;3034-3040.
35. Clayton R.N.et al. Pituitary surgery for acromegaly should be done by specialists. Br. Med. J. 319:1999;588-589.